相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
F. L. Locke et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
Manali Kamdar et al.
LANCET (2022)
Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas
Peter A. Riedell et al.
TRANSPLANTATION AND CELLULAR THERAPY (2022)
Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure
Jordan Gauthier et al.
BLOOD (2020)
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
Loretta J. Nastoupil et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Jeremy S. Abramson et al.
LANCET (2020)
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial
Othman Al-Sawaf et al.
LANCET ONCOLOGY (2020)
Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome
Adam S. Kittai et al.
BLOOD ADVANCES (2020)
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma
Marcelo C. Pasquini et al.
BLOOD ADVANCES (2020)
State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019
Richard Lemal et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution
Juan Pablo Alderuccio et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate
Saar I. Gill et al.
BLOOD (2018)
Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms
M. Ruella et al.
LEUKEMIA (2017)
Ibrutinib treatment improves T cell number and function in CLL patients
Meixiao Long et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Transformation of marginal zone lymphoma (and association with other lymphomas)
Carla Casulo et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2017)
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
Joseph A. Fraietta et al.
BLOOD (2016)
Histologic transformation in marginal zone lymphomas
A. Conconi et al.
ANNALS OF ONCOLOGY (2015)
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
Kami J. Maddocks et al.
JAMA ONCOLOGY (2015)
分享论文
